BioSpace News Archive

Oculis Holding AG (Nasdaq: OCS) (“Oculis” or “the Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced First Patient First Visit (FPFV) in OCS-01 Phase 3 OPTIMIZE-2 trial for the treatment of inflammation and pain following cataract surgery.

Rentschler Biopharma SE announced that the company has secured a major client for the new Rentschler Biopharma Manufacturing Center facility at its manufacturing site in Milford, Massachusetts.

ProMIS Neurosciences Inc. today announced a publication identifying Receptor for Activated C-Kinase 1 (RACK1) as a novel misfolded protein target for ALS and frontotemporal lobar degeneration (FTLD).

OneOne Biosciences, a French startup building a comprehensive suite of agricultural microbial solutions for farmers, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership.

Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced that it will accelerate the repayment of its senior secured loan.

argenx SE announced topline results from the ADDRESS study evaluating efgartigimod subcutaneous in adults with pemphigus vulgaris and pemphigus foliaceus.

PureTech Health plc reports on the key progress made across its Wholly Owned Programs2 and Founded Entities3 in 2023, announces two new Founded Entities and provides an update on cash and operational runway guidance.

Boomerang Medical, Inc., a women-led bioelectronic medicine company focused on autoimmune diseases, proudly announced the completion of Stage 2 of its FDA-approved pilot study.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that data from the first report of an oral, potent, and selective FXIIa inhibitor has been published in the peer-reviewed scientific journal, Frontiers in Pharmacology.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced that the Phase 3 RESILIENT study evaluating TNX-102 SL (cyclobenzaprine HCl sublingual tablets) met its pre-specified primary endpoint in the second of two positive Phase 3 clinical trials, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia (Table 1).